• Regulatory NewsRegulatory News

    ICER to Work With VA on Drug Price Negotiations

    In a first for the Institute for Clinical and Economic Review (ICER), which estimates the cost-effectiveness of drugs, the Department of Veterans Affairs (VA) Pharmacy Benefits Management Services office (PBM) has agreed to use ICER drug assessment reports in drug coverage and price negotiations with the pharmaceutical industry. ICER says it will work with staff in the VA to integrate ICER reports into the VA formulary management process of evaluating the comparativ...
  • Regulatory NewsRegulatory News

    ICER on PD-1 Immunotherapies to Treat Lung Cancer: Lower the Prices

    In a new report on non-small cell lung cancer (NSCLC) treatments, the Institute for Clinical and Economic Review (ICER) found that for PD-1 immunotherapies, which are also often used to treat melanoma, the cost may be too high in terms of lengthening progression-free and overall survival. PD-1 immunotherapies target the checkpoint signaling pathway involving the programmed death 1 (PD-1) receptor, which can help protect tumor cells from being destroyed by the immune syst...
  • Regulatory NewsRegulatory News

    ICER to Re-Evaluate How to Assess Value and Comparative Clinical Effectiveness

    The Institute for Clinical and Economic Review (ICER), an independent nonprofit research institute, on Thursday opened a national call for suggestions on how to improve its value assessment framework, which assesses the comparative clinical effectiveness and value of health care tests, treatments and delivery systems. The call for comments, which are expected to come before 12 September, will help inform ICER’s 2017 update to the methods that underpin its evidence repo...